Literature DB >> 17214084

New routes for delivery of anti-epileptic medications.

Robert S Fisher1, David K Chen.   

Abstract

Use of novel drug delivery methods might enhance efficacy and reduce toxicity, in comparison with currently existing oral anti-epileptic drugs (AEDs). Novel methods aim to deliver optimal drug concentration more specifically to the seizure focus or foci. In this review, we first consider unconventional routes of drug delivery to the peripheral system, then potential new methods of targeted CNS drug delivery. Intrathecal or intraventricular AEDs might circumvent systemic toxicity. Drug-eluting wafers could be surgically positioned over an epileptogenic region of brain. Drug can be delivered to a seizure focus by an implanted catheter and subcutaneous pump. Inactive prodrugs, given systemically, can be made active only at the seizure focus, by interaction with locally-released substances. Liposomes and polysomes are engineered slow-release storage vehicles for drugs. Targeting components can hold liposomes near a region of interest, provided that they can penetrate the blood brain barrier. Lastly, we discuss future prospects for the use of transplanted cells and genes as potential vehicles for local delivery of renewable anti-epileptic regimen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17214084

Source DB:  PubMed          Journal:  Acta Neurol Taiwan        ISSN: 1028-768X


  10 in total

1.  Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321.

Authors:  Dale Ding; Charles W Kanaly; Thomas J Cummings; James E Herndon; Raghu Raghavan; John H Sampson
Journal:  Neurol Res       Date:  2009-12-21       Impact factor: 2.448

2.  Locomotor differences in Mongolian gerbils with the effects of midazolam administration in the form of eye drops.

Authors:  Akcan Akkaya; Umit Y Tekelioglu; Abdullah Demirhan; Mesut Erdurmus; Tayfun Apuhan; Hakan Bayir; Erol Ayaz; Hasan Kocoglu
Journal:  Afr Health Sci       Date:  2014-03       Impact factor: 0.927

3.  Astrocytes derived from fetal neural progenitor cells as a novel source for therapeutic adenosine delivery.

Authors:  Annelies Van Dycke; Robrecht Raedt; Alain Verstraete; Panos Theofilas; Wytse Wadman; Kristl Vonck; Detlev Boison; Paul Boon
Journal:  Seizure       Date:  2010-06-17       Impact factor: 3.184

4.  Convection-enhanced delivery of botulinum toxin serotype A into the nonhuman primate cisterna magna and hippocampus.

Authors:  Davis P Argersinger; Stuart Walbridge; Nicholas M Wetjen; Alexander O Vortmeyer; Tianxia Wu; John A Butman; John D Heiss
Journal:  J Neurosurg       Date:  2019-07-19       Impact factor: 5.115

Review 5.  Advances in the application of technology to epilepsy: the CIMIT/NIO Epilepsy Innovation Summit.

Authors:  Steven C Schachter; John Guttag; Steven J Schiff; Donald L Schomer
Journal:  Epilepsy Behav       Date:  2009-09       Impact factor: 2.937

6.  Long-lasting attenuation of amygdala-kindled seizures after convection-enhanced delivery of botulinum neurotoxins a and B into the amygdala in rats.

Authors:  Maciej Gasior; Rebecca Tang; Michael A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  2013-06-14       Impact factor: 4.030

7.  Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.

Authors:  Dale Ding; Charles W Kanaly; Darrell D Bigner; Thomas J Cummings; James E Herndon; Ira Pastan; Raghu Raghavan; John H Sampson
Journal:  J Neurooncol       Date:  2009-11-07       Impact factor: 4.130

Review 8.  Technology insight: neuroengineering and epilepsy-designing devices for seizure control.

Authors:  William C Stacey; Brian Litt
Journal:  Nat Clin Pract Neurol       Date:  2008-02-26

Review 9.  Convection-enhanced delivery in the treatment of epilepsy.

Authors:  Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

Review 10.  Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies.

Authors:  Manuela Gernert; Malte Feja
Journal:  Pharmaceutics       Date:  2020-11-24       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.